What is Aedicell?
Aedicell operates at the intersection of biotechnology and clinical wound care, providing sophisticated therapeutic solutions designed to address complex tissue damage. The company distinguishes itself through the application of innovative human amnion, chorion, umbilical cord, and placental disk tissue technologies. By prioritizing both clinical efficacy and cost-efficiency, Aedicell offers healthcare providers a compelling alternative to traditional wound care modalities. Their product suite is engineered to facilitate superior healing outcomes for chronic ulcers and acute wounds, effectively bridging the gap between high-performance regenerative medicine and accessible, scalable healthcare delivery.
How much funding has Aedicell raised?
Aedicell has raised a total of $93K across 1 funding round:
Debt
$93K
Debt (2021): $93K with participation from PPP
Key Investors in Aedicell
PPP
Public-Private Partnership
What's next for Aedicell?
With the recent infusion of capital, Aedicell is poised to transition into a more aggressive phase of commercial scaling. The strategic focus will likely shift toward expanding clinical adoption and optimizing supply chain logistics to maintain its cost-advantage in the market. As the company matures through its current growth stage, stakeholders will be monitoring the integration of its tissue-based therapies into broader hospital networks and the potential for further research and development into next-generation regenerative applications. This financial milestone provides the necessary runway to solidify Aedicell's reputation as a leader in the wound care sector while continuing to drive value for both clinical partners and patients.
See full Aedicell company page
